Latest profit margin for Corline Biomedical AB: -102.23% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2026
Trailing 12 months ending Sep 2026
The latest profit margin for CLBIO.ST is -102.23% as of September 2026. That compares with -315.49% in the prior-year period — up 67.6% year over year. That is below the Healthcare sector average of 21.75%. Investors often review this figure alongside Corline Biomedical AB's historical trend and sector peers before judging valuation or financial health.
Over the past year, CLBIO.ST's profit margin moved from -315.49% to -102.23% — a 67.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Corline Biomedical AB's valuation or profitability profile.
Against Healthcare companies, CLBIO.ST currently prints -102.23% for profit margin, while the sector average sits near 21.75%. That is roughly 570.1% below the sector mean. Large gaps often invite a closer look at Corline Biomedical AB's growth, margins, and balance sheet.
Profit Margin shows how effectively Corline Biomedical AB converts resources into returns. At -102.23%, CLBIO.ST may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -315.49% in the prior-year period — up 67.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting CLBIO.ST's profit margin (-102.23%), review year-over-year change from -315.49%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.